Join us for the second installment of the Innovation Showcase, where we introduce visionary ideas rooted in tangible practice to drive meaningful, measurable impact on health care. In this virtual event we will focus on the emergent use of psychedelics for treatment of mental health conditions.

Clinical trials of these drugs have shown promising impacts on symptoms of depression and PTSD often considered “treatment-resistant.” This news has sparked a surge in interest in the use of psychedelics and ketamine for mental health conditions, but there is still much to understand about the broader implications for health care.

Join us on February 13 to:

• Discover the promise, risks, and quickly evolving landscape of psychedelics for mental health treatment 
• Discuss the latest in psychedelic research, including the economic aspects of psychedelic-assisted therapies
• Learn how employers and industry partners are navigating the integration of psychedelic-assisted therapies into mental health strategies

Location & Time

Webinar

February 13, 12:00 p.m. - February 13, 02:00 p.m. E.T.

Speakers

• Elliot Marseille, DrPH, Director | Collaborative for the Economics of Psychedelics
• Sherry Rais, CEO & Co-Founder | Enthea
• Marcus Capone, CEO & Co-Founder | TARA Mind
• Richard Nockowitz, Chief Medical Officer | TARA Mind
• Brian Dolan, Presidentr | TARA Mind
• Charlie Smith, MD, Chief Medical Officer | Aon Health Solutions
• Melissa Lavasani, CEO & Founder | Psychedelic Medicine Coalition